drugset / Trial / NCT01143272

Probiotic Saccharomyces Boulardii for the Prevention of Antibiotic-associated Diarrhoea

NCT01143272

RandomizedParallel-groupQuadruple-blindPrevention

Summary

When patients in hospitals receive antibiotics they often develop diarrhoea. The consequences may be grave for the patient. Thus far, no preventive measure is available. The investigators hypothesize that the apathogenic yeast Saccharomyces boulardii, administered in addition to the antibiotic, may prevent episodes of diarrhoea or may lead to less pronounced diarrhoea. To test this hypothesis, the investigators are carrying out a clinical trial in 1520 adult patients in several hospitals.

Timeline

Start
2010-06
Primary completion
2012-10
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Saccharomyces boulardii Other / unclassified 250 mg Oral